These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 34295689)

  • 1. Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer.
    Duchemann B; Remon J; Naigeon M; Cassard L; Jouniaux JM; Boselli L; Grivel J; Auclin E; Desnoyer A; Besse B; Chaput N
    Transl Lung Cancer Res; 2021 Jun; 10(6):2937-2954. PubMed ID: 34295689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
    Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy through the Lens of Non-Small Cell Lung Cancer.
    Stanley R; Flanagan S; Reilly DO; Kearney E; Naidoo J; Dowling CM
    Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.
    Remon J; Passiglia F; Ahn MJ; Barlesi F; Forde PM; Garon EB; Gettinger S; Goldberg SB; Herbst RS; Horn L; Kubota K; Lu S; Mezquita L; Paz-Ares L; Popat S; Schalper KA; Skoulidis F; Reck M; Adjei AA; Scagliotti GV
    J Thorac Oncol; 2020 Jun; 15(6):914-947. PubMed ID: 32179179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a predictive metabolic signature of response to immune checkpoint inhibitors in non-small cell lung cancer: METABO-ICI clinical study protocol.
    Sannicolo S; Giaj Levra M; Le Gouellec A; Aspord C; Boccard J; Chaperot L; Toussaint B; Moro-Sibilot D; Hannani D; Toffart AC
    Respir Med Res; 2021 Nov; 80():100845. PubMed ID: 34242975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Oncology Biomarkers in Lung Cancer: an Overview.
    Travert C; Barlesi F; Greillier L; Tomasini P
    Curr Oncol Rep; 2020 Aug; 22(11):107. PubMed ID: 32803433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Long-Term and Short-Term Efficacy of Immunotherapy in Non-Small Cell Lung Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis.
    Chu X; Niu L; Xiao G; Peng H; Deng F; Liu Z; Wu H; Yang L; Tan Z; Li Z; Zhou R
    Front Immunol; 2022; 13():875488. PubMed ID: 35693805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Current Status and Future Directions.
    Bhalla S; Doroshow DB; Hirsch FR
    Cancer J; 2020; 26(6):507-516. PubMed ID: 33298722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?
    Costantini A; Takam Kamga P; Dumenil C; Chinet T; Emile JF; Giroux Leprieur E
    Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31470546
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
    Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
    Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
    Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC.
    Goh KY; Cheng TY; Tham SC; Lim DW
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.
    Buder-Bakhaya K; Hassel JC
    Front Immunol; 2018; 9():1474. PubMed ID: 30002656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
    Schett A; Rothschild SI; Curioni-Fontecedro A; Krähenbühl S; Früh M; Schmid S; Driessen C; Joerger M
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):121-131. PubMed ID: 31745593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liquid Biopsy Biomarkers for Immunotherapy in Non-Small Cell Lung Carcinoma: Lessons Learned and the Road Ahead.
    Hita-Millan J; Carracedo A; Fernandez-Rozadilla C
    J Pers Med; 2021 Sep; 11(10):. PubMed ID: 34683113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11).
    Kim H; Kim DW; Kim M; Lee Y; Ahn HK; Cho JH; Kim IH; Lee YG; Shin SH; Park SE; Jung J; Kang EJ; Ahn MJ
    Cancer; 2022 Feb; 128(4):778-787. PubMed ID: 34705268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
    Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer: A review.
    Hao Y; Zhang X; Yu L
    Front Oncol; 2022; 12():911906. PubMed ID: 36052257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.